EGFR and hepatocellular carcinoma: Intriguingly, EGFR (rs1050171, COSM1451600) was present in 75% of the cohort overall, it showed complete penetrance (100%) in early-stage HCC, consistent with reports in glioblastoma (Loriguet et al., 2018) and esophageal cancer (Showeil et al., 2016).